graph Evidence gap map comparisons
combined BRAF-MEK inhibitorsKRAS gene alteration targeted therapyMET gene alteration targeted therapyNTRK gene alteration targeted therapyRET gene alteration targeted therapy
trametinib plus dabrafenib sotorasib capmatinib entrectinib larotrectinib pralsetinib selpercatinib
Comparator:  vs docetaxel; 
Risk of bias:  low;   some concerns;   high;  NA;